Moderna or Vortex; Which pharmaceutical stocks are the most suitable for investment in 2026?

Source link: Moderna or Vertex; Which pharmaceutical stocks are the most suitable for investment in 2026? The competition between Moderna Company and Vertex Pharmaceutical Company is a confrontation between two different models in the biotechnology industry; One by relying on Arane messenger technology and the development of new vaccines and treatments, and the other by relying on sustainable profitability, drugs for specific diseases and the gradual expansion of the product portfolio. The main question for investors in 2026 is: Is the capacity

The competition between Moderna Company and Vertex Pharmaceutical Company is a confrontation between two different models in the biotechnology industry; One by relying on Arane messenger technology and the development of new vaccines and treatments, and the other by relying on sustainable profitability, drugs for specific diseases and the gradual expansion of the product portfolio. The main question for investors in 2026 is: Can the growth capacity of new technologies challenge the financial superiority of a profitable company?

Moderna is looking to expand its messenger technology from covid vaccines to other diseases and cancer treatment.

Vertex has a strong position in the cystic fibrosis drug market and is developing new areas.

With operating loss and negative cash flow, Moderna has more financial risk for investors.

With high profitability, positive cash flow and an improved earnings outlook, Vertex has a stronger financial backing.

Moderna; Technological capacity against financial pressure

Moderna has turned Arani's messenger technology into a platform for developing new vaccines and treatments. The company's products are mainly in the field of infectious diseases, but cooperation in the field of cancer treatment and the development of new products can diversify its sources of income in the long term.

However, declining demand for Covid vaccines has put a lot of pressure on the company's financial performance. Moderna's revenue in 2025 reached about 1.9 billion dollars, which was a decrease of almost 39% compared to the previous year. The company also posted a net loss of about $2.8 billion and negative free cash flow of nearly $2.1 billion.

These figures show that Moderna's scientific success has not yet turned into a sustainable and profitable revenue model. Therefore, the value of investing in this company is highly dependent on the success rate of future products and the ability to manage heavy research and development costs.

vortex; Combining profitability and product development

Vertex has a strong position in the market for drugs for cystic fibrosis, a genetic disease affecting the lungs and digestive system. While maintaining its core business, the company has also invested in areas such as pain control, genetic therapies and kidney disease.

In 2025, Vertex's revenue will reach about $12.1 billion; An increase of nearly 9.6% compared to the previous year. The company's net profit was about $4 billion and its free cash flow was about $3.2 billion. The net profit margin of nearly 32.7% also shows the company's high ability to convert sales into profit.

Vertex's management raised its Q2 2026 annual revenue outlook, according to the report. However, the success of new products is still dependent on the results of clinical trials, regulatory approval and market acceptance.

"From an analytical point of view, the main difference between these two companies is the gap between technology capacity and its conversion into economic efficiency. Moderna has a valuable technological asset, but until product development leads to recurring revenue and stable cash flow, scientific capacity cannot be considered equivalent to realized investment value. Vertex now provides stronger financial evidence of profitability; However, stock prices and future growth expectations are still decisive. A quality company is not necessarily a cheap stock, and a promising technology is not necessarily a profitable investment. »

Moderna faces intense competition in the vaccine market, high product development costs, and intellectual property rights disputes. In contrast, Vertex's significant focus on cystic fibrosis drugs increases the risk of dependence on a single therapeutic area. The suspension of some research programs and the complexity of the production of genetic treatments are also among the challenges of this company.

In terms of valuation, the price-to-sales ratio announced for Moderna is around 40.1x and for Vertex around 10.3x. Vertex's forward-looking price-to-earnings ratio is also reported at 27.3 times, while no comparable figure has been provided for Moderna. This difference shows that the market may place a high value on Moderna's future growth capacity; But the realization of this value depends on the actual performance of its products.

With stabilized profitability, higher revenue and positive cash flow, Vertex is in a more stable financial position. Moderna, on the other hand, has high potential growth capacity, but its trajectory depends on the success of new products and a return to profitability. The choice between the two ultimately depends on the risk tolerance and time horizon of the investor.

Artificial intelligence has been used to translate some parts of this report.